JP2016502973A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502973A5
JP2016502973A5 JP2015545855A JP2015545855A JP2016502973A5 JP 2016502973 A5 JP2016502973 A5 JP 2016502973A5 JP 2015545855 A JP2015545855 A JP 2015545855A JP 2015545855 A JP2015545855 A JP 2015545855A JP 2016502973 A5 JP2016502973 A5 JP 2016502973A5
Authority
JP
Japan
Prior art keywords
optionally substituted
heterocyclyl
heteroaryl
compound according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545855A
Other languages
English (en)
Japanese (ja)
Other versions
JP6403219B2 (ja
JP2016502973A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/073428 external-priority patent/WO2014089365A1/en
Publication of JP2016502973A publication Critical patent/JP2016502973A/ja
Publication of JP2016502973A5 publication Critical patent/JP2016502973A5/ja
Application granted granted Critical
Publication of JP6403219B2 publication Critical patent/JP6403219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545855A 2012-12-07 2013-12-05 ベータ−ラクタマーゼ阻害剤 Active JP6403219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US61/734,900 2012-12-07
US201361783238P 2013-03-14 2013-03-14
US61/783,238 2013-03-14
PCT/US2013/073428 WO2014089365A1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018114967A Division JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016502973A JP2016502973A (ja) 2016-02-01
JP2016502973A5 true JP2016502973A5 (https=) 2016-12-01
JP6403219B2 JP6403219B2 (ja) 2018-10-10

Family

ID=50884012

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545855A Active JP6403219B2 (ja) 2012-12-07 2013-12-05 ベータ−ラクタマーゼ阻害剤
JP2018114967A Pending JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018114967A Pending JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Country Status (16)

Country Link
US (6) US9422314B2 (https=)
EP (2) EP2928898B1 (https=)
JP (2) JP6403219B2 (https=)
KR (1) KR102147420B1 (https=)
CN (1) CN105026407B (https=)
AU (1) AU2013355110B2 (https=)
BR (1) BR112015013123B1 (https=)
CA (1) CA2893943C (https=)
ES (1) ES2878118T3 (https=)
HR (1) HRP20210879T1 (https=)
IL (1) IL239212B (https=)
PL (1) PL2928898T3 (https=)
PT (1) PT2928898T (https=)
RU (1) RU2654692C2 (https=)
WO (1) WO2014089365A1 (https=)
ZA (1) ZA201504200B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2013355110B2 (en) * 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
KR20150103269A (ko) * 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2750805T3 (es) 2014-05-05 2020-03-27 Rempex Pharmaceuticals Inc Síntesis de sales de boronato y usos de las mismas
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016003929A1 (en) * 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
CA2971763A1 (en) * 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
MX389349B (es) 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
KR102603489B1 (ko) * 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
WO2018199291A1 (ja) * 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
CN111556872B (zh) * 2017-11-01 2024-05-10 梅琳塔治疗公司 硼酸酯衍生物的合成及其用途
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102679411B1 (ko) 2018-04-27 2024-07-01 스미토모 파마 가부시키가이샤 옥소 치환 화합물
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3849562B1 (en) 2018-09-12 2024-06-26 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
BR112021010095A2 (pt) 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas
TW202102230A (zh) * 2019-04-02 2021-01-16 美商維納拓爾斯製藥公司 經口遞送之β-內醯胺酶抑制劑之固體形式及其用途
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
EP4049680A4 (en) 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
US20230114728A1 (en) 2019-11-26 2023-04-13 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
JP2023538645A (ja) * 2020-08-20 2023-09-08 フェーノ・セラピューティクス・カンパニー・リミテッド ボロン酸化合物
EP4225321A4 (en) 2020-10-07 2024-11-20 Venatorx Pharmaceuticals, Inc. PROCESS FOR BORON-CONTAINING COMPOUNDS
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US20250340577A1 (en) * 2021-03-02 2025-11-06 Case Western Reserve University Beta-lactomase inhibitors and uses thereof
JP2024514055A (ja) 2021-04-13 2024-03-28 上海拓界生物医薬科技有限公司 β-ラクタマーゼ阻害剤としてのホウ酸誘導体
CN119384424A (zh) * 2022-02-18 2025-01-28 辉诺生物医药科技(杭州)有限公司 新的硼酸类化合物的晶型及其制备方法
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
WO2025111328A1 (en) 2023-11-21 2025-05-30 VenatoRx Pharmaceuticals, Inc. Citrate coordination complex of an orally-delivered beta-lactamase inhibitor and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
EP1635812A2 (en) 2003-06-10 2006-03-22 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
HRP20212002T1 (hr) 2004-03-30 2022-04-01 Millennium Pharmaceuticals, Inc. Sinteza estera i spojeva borove kiseline
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β-内酰胺酶抑制剂的药物组合物
WO2007065288A2 (en) 2005-12-07 2007-06-14 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CA2705393A1 (en) * 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
WO2009091856A2 (en) * 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
WO2011017125A1 (en) 2009-07-28 2011-02-10 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013014497A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
JP6211418B2 (ja) 2011-09-04 2017-10-11 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
SG11201403254QA (en) 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9464098B2 (en) 2012-12-03 2016-10-11 Hoffmann-La Roche Inc. Substituted triazole boronic acid compounds
AU2013355110B2 (en) * 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
EP2943204B1 (en) * 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
JP6218204B2 (ja) 2014-09-04 2017-10-25 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019118358A1 (en) 2017-12-11 2019-06-20 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors

Similar Documents

Publication Publication Date Title
JP2016502973A5 (https=)
RU2015126912A (ru) Ингибиторы бета-лактамаз
JP2016506419A5 (https=)
JP5242857B2 (ja) Syk阻害剤としてのアミノピリミジン類
NZ603427A (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
JP2016515560A5 (https=)
AU2018346597A1 (en) Inhibiting Ubiquitin Specific Peptidase 30
RU2012119488A (ru) Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором
CA2979537A1 (en) Piperazine carbamates and methods of making and using same
JP2006521359A5 (https=)
AU2017279027A1 (en) Chemical Compounds
AU2019344107B2 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors
AR062937A1 (es) Compuestos que modulan el receptor cb2
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
WO2015003002A1 (en) Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
RU2015135891A (ru) Новые производные пиразола
JP2015509535A5 (https=)
RU2009138600A (ru) Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов
JP2010527983A5 (https=)
JP2017529365A5 (https=)
DK2966079T1 (da) Pyridopyrimidin eller pyrimidopyrimidinforbindelse, fremstillingsmetode, pharmaceutisk præparat og anvendelse heraf
SG10201907667RA (en) Morphinan derivative
JP2016532669A5 (https=)
JP2013525262A5 (https=)
CA3063938A1 (en) Compounds, compositions and methods